Concepts (70)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Hair | 2 | 2025 | 30 | 0.510 |
Why?
|
| Leg Dermatoses | 1 | 2013 | 2 | 0.400 |
Why?
|
| Telangiectasis | 1 | 2013 | 7 | 0.400 |
Why?
|
| Pigmentation Disorders | 1 | 2013 | 22 | 0.400 |
Why?
|
| Purpura | 1 | 2013 | 25 | 0.390 |
Why?
|
| Blister | 1 | 2012 | 19 | 0.380 |
Why?
|
| Ibuprofen | 1 | 2012 | 40 | 0.370 |
Why?
|
| Thigh | 1 | 2012 | 51 | 0.370 |
Why?
|
| Drug Eruptions | 1 | 2012 | 33 | 0.370 |
Why?
|
| Analgesics, Non-Narcotic | 1 | 2012 | 78 | 0.350 |
Why?
|
| Melanosis | 1 | 2009 | 9 | 0.310 |
Why?
|
| Alopecia | 1 | 2008 | 41 | 0.270 |
Why?
|
| Scalp | 1 | 2008 | 57 | 0.270 |
Why?
|
| Hair Diseases | 1 | 2025 | 14 | 0.230 |
Why?
|
| Sweet Syndrome | 1 | 2021 | 10 | 0.170 |
Why?
|
| Myoclonus | 1 | 2021 | 32 | 0.170 |
Why?
|
| Encephalitis | 1 | 2021 | 123 | 0.160 |
Why?
|
| Immunoglobulin Light Chains | 1 | 2014 | 27 | 0.110 |
Why?
|
| Leishmania guyanensis | 1 | 2014 | 3 | 0.110 |
Why?
|
| Lymphoma, B-Cell, Marginal Zone | 1 | 2014 | 58 | 0.100 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2014 | 50 | 0.100 |
Why?
|
| Leukemia, Lymphocytic, Chronic, B-Cell | 1 | 2014 | 175 | 0.100 |
Why?
|
| Emigrants and Immigrants | 1 | 2014 | 169 | 0.090 |
Why?
|
| Thorax | 1 | 2009 | 65 | 0.080 |
Why?
|
| Male | 8 | 2014 | 64534 | 0.070 |
Why?
|
| Middle Aged | 5 | 2014 | 28415 | 0.070 |
Why?
|
| Acneiform Eruptions | 1 | 2008 | 4 | 0.070 |
Why?
|
| Diagnosis, Differential | 3 | 2025 | 1877 | 0.070 |
Why?
|
| Psoriasis | 1 | 2008 | 48 | 0.070 |
Why?
|
| Skin Neoplasms | 1 | 2014 | 904 | 0.060 |
Why?
|
| Dermatitis, Irritant | 1 | 2006 | 3 | 0.060 |
Why?
|
| Povidone-Iodine | 1 | 2006 | 7 | 0.060 |
Why?
|
| Reference Values | 1 | 2008 | 675 | 0.060 |
Why?
|
| Stevens-Johnson Syndrome | 1 | 2006 | 19 | 0.060 |
Why?
|
| Humans | 12 | 2025 | 130555 | 0.060 |
Why?
|
| Anti-Infective Agents, Local | 1 | 2006 | 69 | 0.060 |
Why?
|
| Rickets | 1 | 2006 | 9 | 0.060 |
Why?
|
| Epidermal Cyst | 1 | 2006 | 16 | 0.060 |
Why?
|
| Directive Counseling | 1 | 2006 | 24 | 0.060 |
Why?
|
| Periodic Acid-Schiff Reaction | 1 | 2025 | 5 | 0.060 |
Why?
|
| Dermatology | 1 | 2006 | 30 | 0.060 |
Why?
|
| Aged, 80 and over | 2 | 2014 | 6800 | 0.060 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2008 | 637 | 0.060 |
Why?
|
| Dermatitis, Atopic | 1 | 2006 | 56 | 0.060 |
Why?
|
| Staining and Labeling | 1 | 2025 | 166 | 0.050 |
Why?
|
| Vitamin D Deficiency | 1 | 2006 | 84 | 0.050 |
Why?
|
| Malnutrition | 1 | 2006 | 157 | 0.050 |
Why?
|
| Antibodies, Monoclonal | 1 | 2008 | 981 | 0.040 |
Why?
|
| Cuba | 1 | 2014 | 7 | 0.030 |
Why?
|
| Panama | 1 | 2014 | 15 | 0.030 |
Why?
|
| Adult | 3 | 2014 | 31157 | 0.030 |
Why?
|
| Antiprotozoal Agents | 1 | 2014 | 41 | 0.030 |
Why?
|
| Amphotericin B | 1 | 2014 | 89 | 0.030 |
Why?
|
| Travel | 1 | 2014 | 127 | 0.020 |
Why?
|
| Adalimumab | 1 | 2008 | 21 | 0.020 |
Why?
|
| Infliximab | 1 | 2008 | 61 | 0.020 |
Why?
|
| Failure to Thrive | 1 | 2006 | 87 | 0.010 |
Why?
|
| Tacrolimus | 1 | 2006 | 100 | 0.010 |
Why?
|
| India | 1 | 2006 | 232 | 0.010 |
Why?
|
| Nutritional Requirements | 1 | 2006 | 160 | 0.010 |
Why?
|
| Female | 4 | 2014 | 70425 | 0.010 |
Why?
|
| Equipment Design | 1 | 2006 | 536 | 0.010 |
Why?
|
| Antibodies, Monoclonal, Humanized | 1 | 2008 | 566 | 0.010 |
Why?
|
| Aged | 2 | 2014 | 20899 | 0.010 |
Why?
|
| United States | 1 | 2014 | 11883 | 0.010 |
Why?
|
| Parents | 1 | 2006 | 1118 | 0.010 |
Why?
|
| Severity of Illness Index | 1 | 2006 | 3031 | 0.010 |
Why?
|
| Follow-Up Studies | 1 | 2006 | 5164 | 0.010 |
Why?
|
| Risk Assessment | 1 | 2006 | 3678 | 0.010 |
Why?
|
| Infant | 1 | 2006 | 13270 | 0.000 |
Why?
|